Table 1 Demographic data of study subjects (n = 99)

Male/female

8/24

10/57

Age, years

53.0 (49.0 to 58.0)

53.0 (50.3 to 57.0)

0.979

BMI, kg/m²

18.5-23.9

22.8 (21.6 to 24.4)

21.8 (21.6 to 23.5)

0.725

WBC count, cells/mm³

5,000-10,000

6,400 (5,536 to 6,844)

5,900 (5,980 to 6,900)

0.745

Hb, g/dl

12-16

12.9 (11.7 to 13.2)

12.6 (12.2 to 12.9)

0.765

Serum creatinine, mg/dl

<1.4

0.90 (0.87 to 1.13)

0.80 (0.79 to 0.87)

0.222

ALT, IU/L

0-40

15.0 (15.0 to 29.1)

16.0 (15.3 to 20.0)

0.976

CRP (mg/dL)

<0.3

0.40 (0.53 to 1.65)

0.22 (0.52 to 1.75)

0.161

Systolic BP, mmHg

<140

130.0 (123.4 to 133.8)

129.0 (114.7 to 142.2)

0.634

Diastolic BP, mmHg

<90

80.0 (76.2 to 82.3)

79.0 (65.8 to 92.7)

0.732

Disease duration, years

14.1 (11.5 to 16.8)

12.0 (11.3 to 15.0)

0.456

Disease activity, HAQ

0.187 (0.11 to 0.80)

0.125 (0.20 to 0.49)

0.917

Physical activity, h/week

0.00 (0.37 to 3.85)

0.50 (1.14 to 2.41)

0.552

Methotrexate:

Weekly dose, mg

NA

12.5 (10.5 to 12.5)

Duration, months

NA

36.0 (45.8 to 77.8)

Prednisolone users/total:

24/32 (75%)

64/67 (95.5%)

Weekly dose, mg

43.7 (35.0 to 48.7)

35.0 (38.9 to 55.3)

0.167

Duration, months

34.0 (32.6 to 105.8)

48.0 (46.4 to 79.2)

0.180

Salazopyrin, users/total:

26/32 (81.25%)

58/67 (86.56)

Weekly dose, mg

7,000 (7,882 to 11,233)

7,000 (9,051 to 11,825)

0.395

Duration, months

53.5 (38.8 to 105.1)

50.0 (51.5 to 86.4)

0.848

Hydroxychloroquine:

22/32 (68.75%)

57/67 (85.07%)

Weekly dose, mg

1,404 (1,404 to 1,968)

1,400 (1,486 to 1,804)

0.241

Duration, months

11.5 (9.2 to 15.7)

13.0 (13.6 to 21.6)

0.644

Celebrex, users/total:

19/32 (59.37)

42/67 (62.68%)

Weekly dose, mg

1,400 (1,581 to 2,250)

1,400 (1,561 to 2,005)

0.660

Duration, months

18.0 (14.0 to 30.8)

23 (-8.7 to 123.8)

0.829

Meloxicam, users/total:

10/32 (31.3%)

26/67 (38.8%)

Weekly dose, mg

105 (78.6 to 110.3)

105 (78.8 to 98.8)

0.336

Duration, months

7.5 (0.78 to 23.6)

12.0 (9.6 to 27.4)

0.599